These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Different response to the long-acting somatostatin analogues lanreotide and octreotide in a patient with a malignant carcinoid. Raderer M; Kurtaran A; Scheithauer W; Fiebiger W; Weinlaender G; Oberhuber G Oncology; 2001; 60(2):141-5. PubMed ID: 11244329 [TBL] [Abstract][Full Text] [Related]
3. Efficacy of octreotide in the regression of a metastatic carcinoid tumour despite negative imaging with In-111-pentetreotide (Octreoscan). Hillman N; Herranz L; Alvarez C; Martínez Olmos MA; Márco A; Gómez-Pan A Exp Clin Endocrinol Diabetes; 1998; 106(3):226-30. PubMed ID: 9710364 [TBL] [Abstract][Full Text] [Related]
4. Carcinoid of the pancreas. Migliori M; Tomassetti P; Lalli S; Casadei R; Santini D; Corinaldesi R; Gullo L Pancreatology; 2002; 2(2):163-6. PubMed ID: 12123097 [TBL] [Abstract][Full Text] [Related]
5. The cost-effectiveness of octreotide acetate in the treatment of carcinoid syndrome and VIPoma. Schonfeld WH; Eikin EP; Woltering EA; Modlin IM; Anthony L; Villa KF; Zagari M Int J Technol Assess Health Care; 1998; 14(3):514-25. PubMed ID: 9780538 [TBL] [Abstract][Full Text] [Related]
6. Incidence and morbidity of cholelithiasis in patients receiving chronic octreotide for metastatic carcinoid and malignant islet cell tumors. Trendle MC; Moertel CG; Kvols LK Cancer; 1997 Feb; 79(4):830-4. PubMed ID: 9024721 [TBL] [Abstract][Full Text] [Related]
7. [Two cases of thymic carcinoid treated with octreotide long-acting repeatable]. Okabe N; Inoue T; Watanabe Y; Muto S; Hasegawa T; Ohsugi J; Higuchi M; Shio Y; Suzuki H Gan To Kagaku Ryoho; 2014 Jul; 41(7):879-83. PubMed ID: 25131876 [TBL] [Abstract][Full Text] [Related]
8. Sandostatin desensitization--a strategy useful for patients with carcinoid tumors, intolerant to sandostatin. Vinjamaram S; Iyer R Cancer Chemother Pharmacol; 2011 Jul; 68(1):225-6. PubMed ID: 20922390 [TBL] [Abstract][Full Text] [Related]
9. Long-term survival of atypical bronchial carcinoids with liver metastases, treated with octreotide. Filosso PL; Ruffini E; Oliaro A; Papalia E; Donati G; Rena O Eur J Cardiothorac Surg; 2002 May; 21(5):913-7. PubMed ID: 12062286 [TBL] [Abstract][Full Text] [Related]
10. Complete histological regression of metastatic carcinoid tumour after treatment with octreotide. Imtiaz KE; Monteith P; Khaleeli A Clin Endocrinol (Oxf); 2000 Dec; 53(6):755-8. PubMed ID: 11155099 [TBL] [Abstract][Full Text] [Related]
11. Regression of metastatic carcinoid tumors with octreotide therapy: two case reports and a review of the literature. Leong WL; Pasieka JL J Surg Oncol; 2002 Mar; 79(3):180-7. PubMed ID: 11870669 [TBL] [Abstract][Full Text] [Related]
12. [Metastasized carcinoid tumor treated with interferon and octreotide]. Szilvás A; Székely G; Szilvási I; Jakab F Orv Hetil; 1998 Oct; 139(41):2455-8. PubMed ID: 9805460 [TBL] [Abstract][Full Text] [Related]
13. A single-centre experience with octreotide in the treatment of different hypersecretory syndromes in patients with functional gastroenteropancreatic neuroendocrine tumors. Berković MC; Altabas V; Herman D; Hrabar D; Goldoni V; Vizner B; Zjacić-Rotkvić V Coll Antropol; 2007 Jun; 31(2):531-4. PubMed ID: 17847934 [TBL] [Abstract][Full Text] [Related]
14. Intractable hypercalcemia due to a metastatic carcinoid secreting parathyroid hormone-related peptide and interleukin-6: response to octreotide. Barhoum M; Hutchins L; Fonseca VA Am J Med Sci; 1999 Sep; 318(3):203-5. PubMed ID: 10487414 [TBL] [Abstract][Full Text] [Related]
15. Treatment of gastroenteropancreatic neuroendocrine tumours with octreotide LAR. Tomassetti P; Migliori M; Corinaldesi R; Gullo L Aliment Pharmacol Ther; 2000 May; 14(5):557-60. PubMed ID: 10792118 [TBL] [Abstract][Full Text] [Related]
16. An unusual case of metastatic carcinoid tumour in the interventricular septum. Yan AT; Gupta P; Deva D; Choi R; Kirpalani A J Cardiovasc Med (Hagerstown); 2016 Dec; 17 Suppl 2():e126-e128. PubMed ID: 25010506 [TBL] [Abstract][Full Text] [Related]
17. [A case of rectal carcinoid with multiple liver, lymph nodes and bone metastases that responded to an octreotide therapy]. Yamashita K; Takase S; Nakamura T; Matsuda Y; Imanishi T; Sumi Y; Suzuki S; Kamigaki T; Ku Y; Kuroda D Gan To Kagaku Ryoho; 2010 Nov; 37(12):2349-51. PubMed ID: 21224569 [TBL] [Abstract][Full Text] [Related]
18. Single dose of octreotide stabilize metastatic gastro-entero-pancreatic endocrine tumours. Angeletti S; Corleto VD; Schillaci O; Moretti A; Panzuto F; Annibale B; Delle Fave G Ital J Gastroenterol Hepatol; 1999; 31(1):23-7. PubMed ID: 10091100 [TBL] [Abstract][Full Text] [Related]
19. Long-term octreotide treatment of metastatic carcinoid tumor. Corleto VD; Angeletti S; Schillaci O; Marignani M; Caratozzolo M; Panzuto F; Annibale B; Delle Fave G Ann Oncol; 2000 Apr; 11(4):491-3. PubMed ID: 10847473 [TBL] [Abstract][Full Text] [Related]
20. Comparative studies on the expression of somatostatin receptor subtypes, outcome of octreotide scintigraphy and response to octreotide treatment in patients with carcinoid tumours. Nilsson O; Kölby L; Wängberg B; Wigander A; Billig H; William-Olsson L; Fjälling M; Forssell-Aronsson E; Ahlman H Br J Cancer; 1998 Feb; 77(4):632-7. PubMed ID: 9484822 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]